Alaunos TherapeuticsTCRT
About: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
Employees: 1
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 29 [Q3] → 30 (+1) [Q4]
7.5% less ownership
Funds ownership: 12.0% [Q3] → 4.51% (-7.5%) [Q4]
78% less capital invested
Capital invested by funds: $623K [Q3] → $138K (-$485K) [Q4]
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Research analyst outlook
We haven’t received any recent analyst ratings for TCRT.
Financial journalist opinion
